Noveris Health Sciences is trading at $0.13, up 13.04%, on broader biotech-sector momentum.
- Available coverage links the sentiment to Purple Biotech’s U.S. patent allowance for its CAPTN-3 cancer-immunotherapy platform.
- No newly identified company-specific announcement, annual-meeting outcome, or fresh filing explains the intraday gain on September 4, 2026.
- Confidence is Low because the evidence points to sector sentiment rather than a confirmed direct catalyst.